Professor of Medicine, University VA School of Medicine
Oncology
Dr. Paula M. Fracasso, MD
|
|
Give Review
Paula M. Fracasso practices Oncology. She went to Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care She over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Dr. Paula M. Fracasso is a published doctor. She has 74 publications published. The most current publication "Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status ..." She accepts Medicare payments and is registered with Medicare.gov.
Publications
- A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fall...
- A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.
- Reversible Posterior Leukoencephalopathy Syndrome During Regorafenib Treatment: A Case Report and Literature Review of Reversible Posterior Leukoencephalopathy Syndrom...
- Coaching intervention as a strategy for minority recruitment to cancer clinical trials.
- Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian...
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
- A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncolo...
- A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients wit...
- Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and prim...
- Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
- A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovaria...
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
- A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human alpha(v) integrins, intetumumab, in combination with ...
- A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
- Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines.
- Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimall...
- A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
- Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
- Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecolog...
- Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
- A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
- Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
- Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
- Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
- Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
- Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.
- Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
- Pharmacokinetic study of infusional valspodar.
- [Utility of endoscopic follow-up after resection of colorectal cancer].
- Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer''s disease mutation.
- [The Lynch syndrome].
- Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.
- [Irritable colon syndrome: therapeutic activity of otilonium bromide alone or in combination with benzodiazepine. Controlled double-blind study].
- [Tripotassium dicitrato bismuthate in the therapy of peptic ulcer: comparison with ranitidine in short-term treatment].
- Endoscopic dilation of a benign postoperative colonic stenosis with a Sengstaken-Blakemore tube.
- Clinical aspects and management of hereditary non-polyposis colorectal cancer (HNPCC).
- [Colonic varices secondary to recurrent acute pancreatitis].
- Unbalanced germ-line expression of hMLH1 and hMSH2 alleles in hereditary nonpolyposis colorectal cancer.
- Colorectal cancer complicating ulcerative colitis: an institutional series.
- Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status ...
- Turcot syndrome: case report and nosological aspects.
- Recommendations for clinical management of familial adenomatous polyposis.
- Medium-large polyps of the colon: a contribution for their clinical profile and a proper surveillance.
- Novel allele of the hMLH1 gene bearing a TTC deletion in the 3'' untranslated region.
- Failure to diagnose colorectal carcinoma at colonoscopy.
- Endoscopic follow-up in resected colorectal cancer patients.
- Endoscopic follow-up in oncological diseases of the gastrointestinal tract: the experience of the Regina Elena Cancer Institute.
- A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
- Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
- Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
- Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
- Differential changes in genome structure and expression of the mdr gene family in multidrug-resistant murine erythroleukemia cell lines.
- Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
- HPLC method for monitoring SDZ PSC 833 in whole blood.
- Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma.
- Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
- Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
- Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
- Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
- Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study.
- Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancie...
- Overcoming drug resistance in ovarian carcinoma.
- Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
- Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma.
- Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
- Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
- Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
- A phase I study of docetaxel and bexarotene.
- A Phase I trial of weekly docetaxel and topotecan for solid tumors.
- A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.
- A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
Schools
Yale University School Of Medicine
Harvard Med School
Beth Israel Hospital
Post Doctoral Mass Institute Tech
Tufts University
Procedures Preformed
- Thoracentesis
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Tufts Medical Center -
Beth Israel Deaconess Medical Center -
Yale University School of Medicine
Hospital
-
University of Virginia Medical Center
Drug Facts
| NPI NUMBER | 1508895343 | |
| NPPES Provider LastName | FRACASSO | |
| NPPES Provider FirstName | PAULA | |
| NPPES Provider ZIPCode | 229080001 | |
| NPPES Provider State | VA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 27.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508895343 |
| Last Name Of The Provider | FRACASSO |
| First Name Of The Provider | PAULA |
| View All |
Similar Doctors
|
Dr. William W. Grosh Sr., MD |
|
Dr. B Gail Macik, MD |
|
Dr. Patrick M. Dillon, MD |
|
Dr. James E. Boyer, MD |
|
Dr. Thomas P. Loughran, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Zeynel A. Karcioglu, MD |
|
Dr. Stefan M. Gorsch, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thao P. Dang, MD |
|
Dr. Craig A. Portell, MD
This Doctor is OpenDoctor Recommended.
|